These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33488709)

  • 1. Genomic Mutations of Primary and Metastatic Lung Adenocarcinoma in Chinese Patients.
    Chen X; Bu Q; Yan X; Li Y; Yu Q; Zheng H; Zhao L; Zeng Y; Lu L; Lan D; Ma J
    J Oncol; 2020; 2020():6615575. PubMed ID: 33488709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic Features of Organ-Specific Metastases in Lung Adenocarcinoma.
    Feng A; Li Y; Li G; Wang Y; Wen Q; Yang Z; Tian K; Lv H; Guo L; Zhang S; Liu X; Jiang D
    Front Oncol; 2022; 12():908759. PubMed ID: 35912232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.
    Hu C; Zhao L; Liu W; Fan S; Liu J; Liu Y; Liu X; Shu L; Liu X; Liu P; Deng C; Qiu Z; Chen C; Jiang Y; Liang Q; Yang L; Shao Y; He Q; Yu D; Zeng Y; Li Y; Pan Y; Zhang S; Shi S; Peng Y; Wu F
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Mutational Burden Is Site Specific in Non-Small-Cell Lung Cancer and Is Highest in Lung Adenocarcinoma Brain Metastases.
    Stein MK; Pandey M; Xiu J; Tae H; Swensen J; Mittal S; Brenner AJ; Korn WM; Heimberger AB; Martin MG
    JCO Precis Oncol; 2019 Dec; 3():1-13. PubMed ID: 35100709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive values of genomic variation, tumor mutational burden, and PD-L1 expression in advanced lung squamous cell carcinoma treated with immunotherapy.
    Xu Y; Li H; Huang Z; Chen K; Yu X; Sheng J; Zhang HH; Fan Y
    Transl Lung Cancer Res; 2020 Dec; 9(6):2367-2379. PubMed ID: 33489799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma.
    Deng Z; Cui L; Li P; Ren N; Zhong Z; Tang Z; Wang L; Gong J; Cheng H; Guan Y; Yi X; Xia X; Zhou R; He Z
    Cell Death Dis; 2021 Oct; 12(10):935. PubMed ID: 34642306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic alterations dissection revealed
    Yuan C; Yao X; Dai P; Zhao Y; Sun Y
    Transl Lung Cancer Res; 2023 May; 12(5):985-998. PubMed ID: 37323170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive Mutation Profiling of Colorectal Cancer Patients With Lung or Liver Metastasis by Targeted Next-Generation Sequencing.
    Hu CT; Wang JL; Hou T; Yan ZW; Zu LD; Fu GH; Shen WW
    Technol Cancer Res Treat; 2023; 22():15330338231185285. PubMed ID: 37394872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular Signatures of
    Hsu J; Annunziata JF; Burns E; Bernicker EH; Olsen RJ; Thomas JS
    Clin Pathol; 2022; 15():2632010X221102054. PubMed ID: 35634237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
    Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
    Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIM2 upregulation promotes metastatic progression and PD-L1 expression in lung adenocarcinoma.
    Zheng JQ; Lin CH; Lee HH; Chang WM; Li LJ; Su CY; Lee KY; Chiu HW; Lin YF
    Cancer Sci; 2023 Jan; 114(1):306-320. PubMed ID: 36104978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
    Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
    BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development.
    Wang Q; Xie B; Sun J; Li Z; Xiao D; Tao Y; She X
    J Cancer; 2024; 15(6):1687-1700. PubMed ID: 38370388
    [No Abstract]   [Full Text] [Related]  

  • 19. Tumor Mutation Burden and Differentially Mutated Genes Among Immune Phenotypes in Patients with Lung Adenocarcinoma.
    Wang H; Chen S; Meng D; Wu C; Zhu J; Jiang M; Ning J; Wu S; Wu L; Li J; Chen B; Zhao S; Li W; Yu J; Fang Q; Zhu J; Zhao W; He Y; Zhou C
    Onco Targets Ther; 2021; 14():2953-2965. PubMed ID: 33976553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma.
    Liu X; Jiang G; Sun X; Su G; Zhang X; Shen D; Yan N
    Front Oncol; 2023; 13():1275575. PubMed ID: 38023198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.